Deep Track Capital, L.P. 13F annual report
Deep Track Capital, L.P. is an investment fund managing more than $3.35 trillion ran by Nir Messafi. There are currently 67 companies in Mr. Messafi’s portfolio. The largest investments include AMGEN and Argenx Se, together worth $352 billion.
$3.35 trillion Assets Under Management (AUM)
As of 7th August 2024, Deep Track Capital, L.P.’s top holding is 575,000 shares of AMGEN currently worth over $180 billion and making up 5.4% of the portfolio value.
Relative to the number of outstanding shares of AMGEN, Deep Track Capital, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 400,000 shares of Argenx Se worth $172 billion.
The third-largest holding is Axsome Therapeutics Inc worth $149 billion and the next is Dyne Therapeutics worth $141 billion, with 4,000,000 shares owned.
Currently, Deep Track Capital, L.P.'s portfolio is worth at least $3.35 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Deep Track Capital, L.P.
The Deep Track Capital, L.P. office and employees reside in Greenwich, Connecticut. According to the last 13-F report filed with the SEC, Nir Messafi serves as the CCO/COO/CFO at Deep Track Capital, L.P..
Recent trades
In the most recent 13F filing, Deep Track Capital, L.P. revealed that it had opened a new position in
TG Therapeutics Inc and bought 2,870,131 shares worth $51.1 billion.
This means they effectively own approximately 0.1% of the company.
TG Therapeutics Inc makes up
2.0%
of the fund's Health Care sector allocation and has grown its share price by 91.3% in the past year.
The investment fund also strengthened its position in AMGEN by buying
25,000 additional shares.
This makes their stake in AMGEN total 575,000 shares worth $180 billion.
AMGEN soared 23.9% in the past year.
On the other hand, there are companies that Deep Track Capital, L.P. is getting rid of from its portfolio.
Deep Track Capital, L.P. closed its position in Tourmaline Bio Inc on 14th August 2024.
It sold the previously owned 1,595,400 shares for $36.5 billion.
Nir Messafi also disclosed a decreased stake in Dyne Therapeutics by 0.1%.
This leaves the value of the investment at $141 billion and 4,000,000 shares.
One of the largest hedge funds
The two most similar investment funds to Deep Track Capital, L.P. are Members Trust Co and Marsico Capital Management. They manage $3.35 trillion and $3.34 trillion respectively.
Nir Messafi investment strategy
Deep Track Capital, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 75.2% of
the total portfolio value.
The fund focuses on investments in the United States as
53.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
6% of the total holdings value.
On the other hand, large-cap stocks make up only 3.0% of the portfolio.
The average market cap of the portfolio companies is close to $5.72 billion.
The complete list of Deep Track Capital, L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| AMGEN Inc. |
4.55%
575,000
|
$179,658,750,000 | 5.37% |
| Argenx Se |
33.33%
400,000
|
$172,016,000,000 | 5.14% |
| Axsome Therapeutics Inc |
42.01%
1,852,784
|
$149,149,112,000 | 4.45% |
| Dyne Therapeutics, Inc. |
12.19%
4,000,000
|
$141,160,000,000 | 4.22% |
| SpringWorks Therapeutics, Inc. |
6.33%
3,700,000
|
$139,379,000,000 | 4.16% |
| Insmed Inc |
58.19%
2,000,000
|
$134,000,000,000 | 4.00% |
| Guardant Health Inc |
25.00%
4,500,000
|
$129,960,000,000 | 3.88% |
| Dynavax Technologies Corp. |
19.23%
10,900,000
|
$122,407,000,000 | 3.66% |
| Alnylam Pharmaceuticals Inc |
39.93%
500,000
|
$121,500,000,000 | 3.63% |
| Intellia Therapeutics Inc |
13.99%
4,800,000
|
$107,424,000,000 | 3.21% |
| Intra-Cellular Therapies Inc |
2.53%
1,537,922
|
$105,332,278,000 | 3.15% |
| Apellis Pharmaceuticals Inc |
150.00%
2,500,000
|
$95,900,000,000 | 2.86% |
| Ionis Pharmaceuticals Inc |
45.62%
2,000,000
|
$95,320,000,000 | 2.85% |
| Ocular Therapeutix Inc |
No change
12,721,460
|
$87,014,786,000 | 2.60% |
| 4d Molecular Therapeutics In |
33.84%
4,061,401
|
$85,248,807,000 | 2.55% |
| Alkermes plc |
No change
3,500,000
|
$84,350,000,000 | 2.52% |
| Nurix Therapeutics, Inc. |
33.15%
3,991,500
|
$83,302,605,000 | 2.49% |
| Immunovant Inc |
484.52%
2,883,736
|
$76,130,630,000 | 2.27% |
| Bicycle Therapeutics plc |
No change
3,490,506
|
$70,647,841,000 | 2.11% |
| Pliant Therapeutics, Inc. |
3.87%
5,972,257
|
$64,201,763,000 | 1.92% |
| Travere Therapeutics Inc |
No change
7,370,000
|
$60,581,400,000 | 1.81% |
| Verona Pharma Plc |
25.49%
4,000,000
|
$57,840,000,000 | 1.73% |
| Abivax Sa |
2.74%
4,179,763
|
$55,256,467,000 | 1.65% |
| Geron Corp. |
57.39%
13,000,000
|
$55,120,000,000 | 1.65% |
| Autolus Therapeutics plc |
No change
15,272,172
|
$53,147,159,000 | 1.59% |
| TG Therapeutics Inc |
Opened
2,870,131
|
$51,059,630,000 | 1.52% |
| Viridian Therapeutics Inc |
13.54%
3,923,849
|
$51,049,275,000 | 1.52% |
| Kymera Therapeutics, Inc. |
18.84%
1,500,000
|
$44,775,000,000 | 1.34% |
| Mind Medicine Mindmed Inc |
8.44%
6,103,817
|
$44,008,521,000 | 1.31% |
| Olema Pharmaceuticals, Inc. |
24.01%
4,000,000
|
$43,280,000,000 | 1.29% |
| Terns Pharmaceuticals Inc |
No change
6,100,000
|
$41,541,000,000 | 1.24% |
| Spyre Therapeutics Inc |
44.77%
1,756,667
|
$41,299,241,000 | 1.23% |
| Apogee Therapeutics Inc |
56.96%
1,000,000
|
$39,350,000,000 | 1.18% |
| Structure Therapeutics Inc |
2,266.89%
950,000
|
$37,306,500,000 | 1.11% |
| Tourmaline Bio Inc |
Closed
1,595,400
|
$36,534,660,000 | |
| ANI Pharmaceuticals Inc |
43.30%
466,089
|
$29,680,548,000 | 0.89% |
| Editas Medicine Inc |
8.55%
6,000,000
|
$28,020,000,000 | 0.84% |
| Eliem Therapeutics Inc |
Opened
3,904,785
|
$27,763,021,000 | 0.83% |
| Hillevax Inc |
28.76%
1,832,652
|
$26,500,148,000 | 0.79% |
| Pacific Biosciences Calif In |
Closed
7,000,000
|
$26,250,000,000 | |
| Korro Bio Inc |
Opened
770,645
|
$26,101,746,000 | 0.78% |
| Silence Therapeutics plc |
17.28%
1,359,745
|
$25,835,155,000 | 0.77% |
| Nektar Therapeutics |
2.85%
17,875,498
|
$22,165,618,000 | 0.66% |
| Engene Holdings Inc |
No change
2,250,000
|
$21,217,500,000 | 0.63% |
| Alector, Inc. |
22.88%
4,631,998
|
$21,029,271,000 | 0.63% |
| Nuvalent Inc |
Closed
274,512
|
$20,613,106,000 | |
| Agenus Inc |
Closed
31,697,539
|
$18,384,573,000 | |
| 89bio Inc |
Opened
2,294,011
|
$18,375,028,000 | 0.55% |
| Fate Therapeutics Inc |
No change
5,572,607
|
$18,278,151,000 | 0.55% |
| Inovio Pharmaceuticals Inc |
Opened
2,066,720
|
$16,699,098,000 | 0.50% |
| Praxis Precision Medicines I |
Opened
389,546
|
$16,111,623,000 | 0.48% |
| Cybin Inc |
No change
58,139,535
|
$15,755,814,000 | 0.47% |
| Context Therapeutics Inc |
Opened
7,419,355
|
$14,875,807,000 | 0.44% |
| Pyxis Oncology Inc |
No change
4,184,100
|
$13,849,371,000 | 0.41% |
| Neumora Therapeutics Inc. |
Closed
1,000,000
|
$13,750,000,000 | |
| Invivyd Inc |
No change
10,953,937
|
$12,049,331,000 | 0.36% |
| AnaptysBio Inc |
Closed
529,452
|
$11,923,259,000 | |
| Zura Bio Ltd |
30.15%
3,283,783
|
$11,493,241,000 | 0.34% |
| Kura Oncology Inc |
Opened
384,756
|
$7,922,126,000 | 0.24% |
| Ultragenyx Pharmaceutical In |
Closed
167,784
|
$7,833,835,000 | |
| Cytokinetics Inc |
Opened
132,495
|
$7,178,579,000 | 0.21% |
| Regulus Therapeutics Inc |
0.12%
3,262,564
|
$5,823,677,000 | 0.17% |
| Alto Neuroscience Inc |
14.72%
511,686
|
$5,469,923,000 | 0.16% |
| Agenus Inc |
Opened
313,359
|
$5,248,763,000 | 0.16% |
| Allakos Inc |
No change
5,000,000
|
$5,000,000,000 | 0.15% |
| Syros Pharmaceuticals Inc. |
No change
828,485
|
$4,274,983,000 | 0.13% |
| Relmada Therapeutics Inc |
0.42%
1,234,773
|
$3,704,319,000 | 0.11% |
| Edgewise Therapeutics Inc |
Opened
186,386
|
$3,356,812,000 | 0.10% |
| Scholar Rock Hldg Corp |
45.21%
372,559
|
$3,103,416,000 | 0.09% |
| Repare Therapeutics Inc. |
66.31%
904,261
|
$2,984,061,000 | 0.09% |
| Cogent Biosciences, Inc. |
2.46%
308,235
|
$2,598,421,000 | 0.08% |
| Mersana Therapeutics Inc |
Closed
579,674
|
$2,596,940,000 | |
| Vigil Neuroscience Inc |
62.56%
597,215
|
$2,388,860,000 | 0.07% |
| Aligos Therapeutics, Inc. |
No change
6,102,770
|
$2,135,970,000 | 0.06% |
| Prime Medicine Inc |
Closed
303,716
|
$2,126,012,000 | |
| Metagenomi Inc |
No change
466,232
|
$1,902,227,000 | 0.06% |
| No transactions found | |||
| Showing first 500 out of 76 holdings | |||
Hedge funds similar to Deep Track Capital, L.P.
- Rubric Capital Management L.P.
- Systematic Financial Management L.P.
- Perigon Wealth Management
- Bleakley
- Chicago Capital
- Lmr Partners LL.P.
- Members Trust Co
- Marsico Capital Management
- Bls Capital Fondsmaeglerselskab A/s
- Norinchukin Bank, The
- Grimes & Company, Inc
- Continental Casualty
- Wit
- Rock Springs Capital Management L.P.